FDA/CDC

FDA warns kratom vendors about unproven claims


 

The Food and Drug Administration has issued letters of warning to Chillin Mix Kratom and Mitra Distributing for making unproven medical claims about their kratom products – and therefore breaking federal law – according to a statement from FDA commissioner Scott Gottlieb, MD. These vendors both claimed that their kratom products could, among other things, “relieve” or “treat” opium/opioid withdrawal.

The Mitragyna Speciosa tree, from which the drug kratom is produced. ThorPorre/commons.wikimedia.org

The Mitragyna Speciosa tree, from which the drug kratom is produced.

“To date, there have been no adequate and well-controlled studies involving the use of kratom as a treatment for opioid use withdrawal or other diseases in humans,” noted Dr. Gottlieb.

As Dr. Gottlieb pointed out in his statement, not only can fraudulent health claims pose direct health risks, they can also, in the case of kratom, deter or delay people who’re suffering from opioid use disorder from seeking FDA-approved treatments that have been demonstrated to be safe and effective.

Dr. Scott Gottlieb


Kratom, also known more formally as Mitragyna speciosa, is a plant native to Thailand, Malaysia, Indonesia, and Papua New Guinea. Some compounds in the plant are believed to be opioids, some of which may have the potential for abuse. As Dr. Gottlieb pointed out in his statement, the substance is illegal or controlled in several countries and banned in some states and municipalities in the United States.

Find out more in Dr. Gottlieb’s full statement on the FDA website.

Recommended Reading

Barriers loom for HCV care in young people who inject drugs
MDedge Internal Medicine
Treating sleep disorders in chronic opioid users
MDedge Internal Medicine
Opioids, other causes linked to shorter lifespans, rising midlife mortality
MDedge Internal Medicine
CDC: 2017 worst year yet for drug overdoses
MDedge Internal Medicine
Witnessed overdose, HCV infection associated with greater opioid overdose risk
MDedge Internal Medicine
Study examines the world of alcohol use
MDedge Internal Medicine
E-cigarette use highest among adults aged under 35 years
MDedge Internal Medicine
Policy responses to opioid epidemic may have benefits, harms
MDedge Internal Medicine
FDA approves Cassipa for opioid dependence
MDedge Internal Medicine
Medically-treated youths more likely to stay in opioid addiction treatment
MDedge Internal Medicine